Department of Pharmacy, Yuebei People's Hospital, Shaoguan, Guangdong, China.
Biomed Res Int. 2022 Apr 15;2022:2662666. doi: 10.1155/2022/2662666. eCollection 2022.
At present, several studies have assessed the association between ERCC6 rs2228526 polymorphism and the risk of cancer. However, the association remained controversial. To provide a more accurate estimate on the association, we performed a meta-analysis search of case-control studies on the associations of ERCC6 rs2228526 with susceptibility to cancer. PubMed, Embase, Google Scholar, Wanfang database, and Chinese National Knowledge Infrastructure databases (CNKI) China Biological Medicine Database (CBM) (up to August 2021) were searched to identify eligible studies. The effect summary odds ratio (OR) with 95% confidence intervals (CI) was applied to assay the association between the ERCC6 rs2228526 polymorphism and the risk of cancer. 14 studies included 15 case-control studies which contained 5,856 cases, and 6,387 controls were finally determined as qualified studies for this meta-analysis. Overall, based on current studies, we found significant association between ERCC6 rs2228526 polymorphism and the risk of cancer in four genetic models [the allele model G vs. A: 1.10, (1.03-1.17); the homozygous model GG vs. AA: 1.27, (1.07-1.51); heterozygote model GA vs. AA: 1.08, (1.00-1.17); the dominant model GG + GA vs. AA: 1.10, (1.02-1.19); the recessive model GG vs. GA + AA: 1.22, (1.03-1.45)]. In the stratified analysis based on ethnicity, we found significant association in two genetic models in Asians. Further, significant genetic cancer susceptibility was found under PB control on subgroup analysis by source of control. In addition, no significant association was found in lung cancer and bladder cancer patients in subgroup analyses based on cancer style. This study suggests that the ERCC6 rs2228526 polymorphism may be associated with increased cancer risk.
目前，已有几项研究评估了 ERCC6 rs2228526 多态性与癌症风险之间的关联，但关联仍存在争议。为了更准确地评估这种关联，我们对 ERCC6 rs2228526 与癌症易感性相关的病例对照研究进行了荟萃分析搜索。我们检索了 PubMed、Embase、Google Scholar、万方数据库和中国国家知识基础设施数据库（CNKI）中国生物医学文献数据库（CBM）（截至 2021 年 8 月），以确定合格的研究。应用汇总优势比（OR）及其 95%置信区间（CI）来检测 ERCC6 rs2228526 多态性与癌症风险之间的关联。共有 14 项研究纳入了 15 项病例对照研究，共包含 5856 例病例和 6387 例对照，最终确定这 14 项研究符合荟萃分析的条件。总体而言，基于目前的研究，我们发现 ERCC6 rs2228526 多态性与癌症风险之间存在显著关联，在 4 种遗传模型中均有发现 [等位基因模型 G 对 A：1.10（1.03-1.17）；纯合模型 GG 对 AA：1.27（1.07-1.51）；杂合模型 GA 对 AA：1.08（1.00-1.17）；显性模型 GG+GA 对 AA：1.10（1.02-1.19）；隐性模型 GG 对 GA+AA：1.22（1.03-1.45）]。基于种族的分层分析显示，在亚洲人群的两种遗传模型中存在显著关联。此外，通过对照组来源的亚组分析发现，在 PB 对照组下，存在显著的遗传癌症易感性。基于癌症类型的亚组分析显示，在肺癌和膀胱癌患者中未发现显著关联。本研究表明，ERCC6 rs2228526 多态性可能与癌症风险增加有关。
